Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)


  • Duration of virologic suppression is an important factor to consider before modifying an antiretroviral regimen, particularly if there is a need to use regimens of lower potency or lower genetic barrier to resistance
  • Available data from ritonavir-boosted PI monotherapy trials demonstrate more favorable virologic outcomes when this approach is used in patients who have experienced virologic suppression for at least 6 months[Delfraissy 2008; Cameron 2008; Arribas 2005; Pulido 2008a]
    • Very low baseline HIV-1 RNA level is an additional factor for predicting treatment success
  • Switch to a Less Potent Regimen
      Effect of Adherence After Durable Virologic Suppression

      Action required